KLK3 and prostate carcinoma: , standard deviation (S.D.), and 95% credible intervals (CI) for the prostate cancer dataset were obtained using the proposed joint model, focusing on longitudinal PSA and ALP biomarkers and time-to-tumor shrinkage outcomes.